Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Condition: EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
NCT07323056
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.